| Total: $144.02M | ||||
| Company | Type Of | Number | Amount | Investors; Placement Agents; Details (Date)@ |
| | ||||
| Aastrom | Private placement of common stock | 3.3S | $5 | Aastrom placed a total of 3.3M shares during August with Isosceles Fund Ltd., raising $5M (8/27) |
| Antex Biologics Inc. (AMEX: | Private placement of convertible preferred stock and warrants | N/A | $3 | Antex raised $3M in a private placement managed by H.C. Wainwright & Co. Inc.; investors included Xmark LP and Xmark Ltd., both managed by Brown Simpson Asset Management, SDS Merchant Fund LP and S.A.C. Capital Associates LLC (8/1) |
| Aphton Corp. | Private placement of common stock | 1.2S | $14.25 | Aphton raised $14.25M in a private equity financing with several institutional investors, selling about 1.2M shares of common stock at $12 per share (8/27) |
| Aradigm Corp. (ARDM) | Private placement of common stock and warrants | 3.6S and 0.36W | $14.6 | Aradigm raised $14.6M selling about 3.6M shares and warrants to purchase 363,929 shares (8/23) |
| BioTime Inc. | Private placement of 10% nonconvertible debentures and warrants | N/A | $3.5 | BioTime raised $3.5M through the private placement (8/23) |
| Hyseq Inc. | Private placement of common stock | 3.04S | $21.3 | Hyseq raised $21.3M in a private placement that included Narragansett Asset Management, Vulcan Ventures and senior Hyseq management and board members led by George Rathmann, chairman (8/30) |
| Incara | Private placement of common stock and warrants | 4.25S and 1W | $7 | Incara raised $7M in an offering of 4.25M shares and warrants to purchase about 1M shares; investors included Deerfield Capital Management, Merlin Biomed Asset Management and other institutional and private investors; Petkevich & Partners LLC was placement agent (8/10) |
| Neotherapeutics | Private placement of common stock | 0.6S | $2.01M | Neotherapeutics placed 600,000 shares with Summit Capital Management LLC, raising $2.01M (8/14) |
| Ortec | Financing for non-equity capital | N/A | $25 | Ortec completed the financing with Paul Capital Royalty Acquisition Fund for up to $25M (8/30) |
| Synaptic | Private placement of convertible preferred stock | 2.2S | $9.4 | Synaptic raised $9.4M in the first part of a two-part financing; Warburg Pincus & Co. LLC bought the Series B preferred stock, which is convertible into 2.2M shares; the second part of the financing involves Warburg's purchase of as much as $1.6M worth of Series B preferred stock and $30M worth of Series C preferred stock (8/3) |
| Triangle | Private placement of common stock | 9.62S | $25.51 | Triangle raised $25.51M in its first closing of a two-part financing to sell 28.3M shares to Warburg Pincus Private Equity VIII LP for $2.65 per share; the second closing is expected to occur in a little over a month; Bank of America Securities LLC is serving as placement agent (8/24) |
| ViroLogic Inc. | Private placement of warrants | 3.2W | $9.55 | ViroLogic raised $9.55M in the second portion of a $16.25M private placement; the first portion, totaling about $6.7M, closed July 2 (8/30) |
| Viventia Biotech | Private placement of units | 17.9U | C$6 (US$3.9) | Dan Family Holdings Ltd. purchased the units, which each includes one common share and one purchase warrant to buy a common share at 33.5 cents for up to five years (8/27) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available or reported. | ||||
AMEX = American Stock Exchange; TSE = Toronto Stock Exchange | ||||
